Effettuare il login Iscriviti gratis

Cotinga Pharmaceuticals Avanti P/E

Cos'è Avanti P/E di Cotinga Pharmaceuticals?

Avanti P/E di Cotinga Pharmaceuticals, Inc. è -1.63

Qual è la definizione di Avanti P/E?



Il rapporto prezzo / utili a termine è il rapporto tra il prezzo delle azioni di una società e l'utile stimato per azione della società per i prossimi dodici mesi.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Avanti P/E di aziende nel Health Care settore su TSXV rispetto a Cotinga Pharmaceuticals

Cosa fa Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Aziende con avanti p/e simili a Cotinga Pharmaceuticals